A new peptide to help deliver treatments for depression to the brain
Official title: Nicotinic receptor selective cell penetrating peptide for brain cargo delivery
Funded at University of Alaska Fairbanks · NIH-10984476 · Data updated 2026-11-12
This study is exploring a new way to help teenagers and young adults with depression by using a special peptide that can carry treatments directly into the brain, aiming to make existing therapies work better and have fewer side effects.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alaska Fairbanks NIH-funded |
| Lab location | 1 site (Fairbanks, United States) |
| Project start | November 10, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $65,875 |
| NIH project number | 5R03MH135358-02 |
| Project ID | NIH-10984476 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents and young adults suffering from major depressive disorder who have not found relief with existing treatments.
✕Less likely to help
Patients with depression who are already responding well to current pharmacological treatments may not benefit from this research.
What this research studies
This research focuses on developing a specialized peptide that can effectively deliver therapeutic agents across the blood-brain barrier to treat major depressive disorder (MDD), particularly in adolescents and young adults. The approach involves targeting nicotinic acetylcholine receptors, which are implicated in depression, to enhance the delivery of treatments that can increase brain-derived neurotrophic factor (BDNF) levels. By using a selective cell-penetrating peptide, the research aims to improve the efficacy of existing therapies and reduce side effects associated with current medications. The study will involve testing this peptide's ability to transport therapeutic agents in preclinical models.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for major depressive disorder, particularly for those who do not respond to current therapies.
How similar studies have gone: While the approach of using cell-penetrating peptides is promising, this specific application targeting nicotinic receptors in depression is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of Alaska Fairbanks
Fairbanks, United States Active
Researchers
- Principal investigator: Weltzin, Maegan M — University of Alaska Fairbanks
- Study coordinator: Weltzin, Maegan M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.